Microvascular alteration is a statistically significant determinant for diabetic peripheral neuropathy prevalenceNew data reveals key drivers of nerve damage in diabetes

This meta-analysis synthesized data from a large population of 83,560 patients across 24 countries to evaluate the prevalence and pathophysiological hallmarks of diabetic peripheral neuropathy (DPN). The study aimed to identify key risk factors and determine which hallmark mechanisms—including neuronal damage, metabolic dysregulation, neuroinflammation, and microvascular alteration—contribute significantly to the condition.

The primary outcome was the global prevalence of DPN. The analysis reported a global prevalence of 57.42% (95% CI: 48.56 to 66.05). Regional analyses revealed varying prevalence rates: 74.52% in the Americas, 59.95% in Europe, and 45.44% in Asia. These figures suggest a high burden of DPN globally, with significant regional variation.

Regarding the underlying mechanisms, microvascular alteration was identified as a statistically significant mechanistic determinant (Q = 15.78, p = 0.0004). Furthermore, the prevalence of microvascular alteration showed a positive correlation with severity scores, escalating monotonically from 53% to 92%. Other hallmark mechanisms included neuronal damage, metabolic dysregulation, and neuroinflammation; however, the study specifically highlighted microvascular alteration as the statistically significant determinant among those evaluated.

Several risk factors were analyzed to determine their association with DPN. Peripheral vascular disease was found to be a significant risk factor (OR: 3.70). Additionally, male sex (OR: 1.52) and height (OR: 1.26) were identified as statistically significant risk factors for the condition. In contrast, several common clinical metrics including HbA1c, BMI, and blood pressure were found to be nonsignificant risk factors in this specific analysis.

The findings suggest that while many factors contribute to DPN, microvascular alterations play a distinct role in both the presence and severity of the disease. The correlation between microvascular alteration and severity scores (53% to 92%) suggests that vascular involvement may be a key indicator for clinical progression. These results support a precision medicine framework where DPN is managed through hallmark stratified phenotyping and mechanism-targeted pharmacotherapy.

Methodological limitations were not reported, and safety or tolerability outcomes were not available. The study does not establish causality but identifies significant associations between specific risk factors and DPN. Clinicians may find these results useful for identifying high-risk patients based on vascular markers rather than solely relying on metabolic markers like HbA1c or BMI. Future research is needed to determine how these identified mechanisms can be targeted specifically in clinical practice to improve outcomes for the 57.42% of patients affected globally.